Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-14T06:00:22.668Z Has data issue: false hasContentIssue false

11 - Neurocognitive Disorders

Published online by Cambridge University Press:  22 July 2021

By
Brent P. Forester ,
Feyza Marouf ,
Ben Legesse ,
Olivia I. Okereke  and
Deborah Blacker
Edited by
Audrey Walker ,
Steven Schlozman  and
Jonathan Alpert
Audrey Walker
Affiliation:
Albert Einstein College of Medicine, New York
Steven Schlozman
Affiliation:
Harvard Medical School
Jonathan Alpert
Affiliation:
Albert Einstein College of Medicine, New York
Get access

Summary

Cognitive disorders in the DSM-IV-TR included delirium, dementia, amnestic disorder, and cognitive disorders not otherwise specified. DSM-V retains the diagnosis of delirium and introduces the term neurocognitive disorder (NCD), dividing NCDs into major NCD or mild NCD and unspecified NCD. The diagnostic category of major NCD encompasses syndromes that were previously categorized as dementia and amnestic disorder. Memory loss is no longer an essential criterion for major NCD in DSM-V as it was for dementia in DSM-IV-TR. Major NCD also includes progressive neurodegenerative dementias, as well as static cognitive disorders that are not expected to worsen over time. The term dementia is retained in DSM-V because of familiarity of the term to the public and medical practitioners.

Type
Chapter
Information
Introduction to Psychiatry
Preclinical Foundations and Clinical Essentials
 , pp. 263 - 288
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References and Suggested Readings

Alexopoulos, G. S., Meyers, B., Young, R. C. et al. (2000). Executive Dysfunction and Long-Term Outcomes of Geriatric Depression. Arch Gen Psychiatry, 57, 285–290.CrossRefGoogle ScholarPubMed
Alzheimer’s Association (2020). Alzheimer’s Disease Facts and Figures. New York: Alzheimer’s Association.Google Scholar
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Arlington, VA: American Psychiatric Association.Google Scholar
Banerjee, S., Hellier, J., Dewey, M., et al. (2011). Sertraline or Mirtazapine for Depression in Dementia (HTA-SADD): A Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial. Lancet, 378, 403–411.CrossRefGoogle ScholarPubMed
Ballard, C., Creese, B., Corbett, A., and Aarsland, D. (2011). Atypical Antipsychotics for the Treatment of Behavioral and Psychological Symptoms in Dementia, with a Particular Focus on Longer Term Outcomes and Mortality. Expert Opin Drug Saf, 10, 35–43.CrossRefGoogle ScholarPubMed
Cummings, J., and Mega, M. (2003). Neuropsychiatry and Behavioral Neuroscience. New York: Oxford University Press.Google Scholar
Gitlin, L. N., Kales, H. C., and Lyketsos, C. G. (2012). Non-Pharmacologic Management of Behavioral Symptoms in Dementia. JAMA, 308 (19), 2020–2029.CrossRefGoogle Scholar
Inouye, S. K. (2006). Delirium in Older Persons. NEJM, 354 (11), 1157–1165.CrossRefGoogle ScholarPubMed
Jack, C. R., Jagust, W. J., Petersen, R. C., et al. (2013). Tracking Pathophysiological Processes in Alzheimer’s Disease: An Updated Hypothetical Model of Dynamic Biomarkers. Lancet Neurol, 12, 207–216.CrossRefGoogle ScholarPubMed
Kales, H. C., Kim, H. M., Zivin, K., et al. (2012). Risk of Mortality among Individual Antipsychotics in Patients with Dementia. Am J Psychiatry, 169, 71–79.CrossRefGoogle ScholarPubMed
Kavirajan, H., and Schneider, L. S. (2007). Efficacy and Adverse Effects of Cholinesterase Inhibitors and Memantine in Vascular Dementia: A Meta-Analysis of Randomised Controlled Trials. Lancet Neurol, 6 (9), 782–792.CrossRefGoogle ScholarPubMed
Lacasse, H., Perreault, M. M., and Williamson, D. R. (2006). Systematic Review of Antipsychotics for the Treatment of Hospital-Associated Delirium in Medically or Surgically Ill Patients. Ann Pharmacother, 40 (11), 1966–1973.CrossRefGoogle ScholarPubMed
Petersen, R. C. (2011). Mild Cognitive Impairment. NEJM, 364, 2227–2234.CrossRefGoogle ScholarPubMed
Rolinski, M., Fox, C., Maidment, I., and McShane, R. (2012). Cholinesterase Inhibitors for Dementia with Lewy Bodies, Parkinson’s Disease Dementia and Cognitive Impairment in Parkinson’s Disease. Cochrane Database Syst Rev, 3, CD006504.Google Scholar
Schulz, R., and Beach, S. (1999). Caregiving as a Risk Factor for Mortality: The Caregiver Health Effects Study. JAMA, 282, 2215–2219.CrossRefGoogle ScholarPubMed
Seitz, D. P., Adunuri, N., Gill, S. S., et al. (2011). Antidepressants for Agitation and Psychosis in Dementia. Cochrane Database Syst Rev, CD008191.CrossRefGoogle Scholar
Tariot, P. N., Farlow, M. R., Grossberg, G. T., et al. (2004). Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. JAMA 291 (3), 317–324.CrossRefGoogle ScholarPubMed
Vigen, C. L., Mack, W. J., Keefe, R. S., et al. (2011). Cognitive Effects of Atypical Antipsychotic Medications in Patients with Alzheimer’s Disease: Outcomes from CATIE-AD. Am J Psychiatry, 168, 831–839.CrossRefGoogle ScholarPubMed
Witlox, J., Eurelings, L. S., de Jonghe, J. F., et al. (2010). Delirium in Elderly Patients and the Risk of Postdischarge Mortality, Institutionalization, and Dementia: A Meta-analysis. JAMA 304, 443– 451.CrossRefGoogle ScholarPubMed
Yaffe, K., Blackwell, T., Gore, R., et al. (1999). Depressive Symptoms and Cognitive Decline in Nondemented Elderly Women: A Prospective Study. Arch Gen Psychiatry, 56 (5), 425–430.CrossRefGoogle ScholarPubMed
Yudovsky, S., and Hales, R. (eds.) (2007). The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, 5th edition. Arlington, VA: American Psychiatric Publishing.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×